Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eoghan Muholland

Dr Eoghan Mulholland, Postdoctoral Research Scientist in Cancer Genetics at the Wellcome Centre for Human Genetics and member of Somerville College has recently been awarded the Lee Placito Research Fellowship in Gastrointestinal Cancer.

Colorectal cancer (CRC) is currently the 2nd most common cause of cancer death in the UK. To date, research tells us that it isn’t just the genetic defects in the cancer cells that influences how a cancer behaves, but also how the supporting (stromal) and immune cells interact with it. Currently we don’t fully understand how these ‘cell conversations’ initiate and develop but using cutting-edge research methodologies we can have the opportunity to ‘eavesdrop’. Using the Lee Placito Fellowship, Dr Mulholland  will focus in on these cellular exchanges to better understand how cancer cells, stromal cells and immune cells interact with each other across both human tissue and in Genetically Engineered Mouse Models. Through better understanding of this we can then hope to influence how the cells conversation, change the CRC dynamics, and ultimately improve treatment.

On receiving this Fellowship, Dr Mulholland commented:Using the Lee Placito Fellowship, I will focus in on the ‘cell conversations’ between cancer cells, stromal cells and immune cells. Through better understanding of this we can then hope to influence how the cells communicate, change the colorectal cancer dynamics, and ultimately improve treatment.’

Find out more about the Lee Placito Research Fellowship

Similar stories

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.